Financial Market News

Factories raised prices even as orders shrank, Williams-Sonoma met forecasts and fell 15%, and nearly $2 billion left a stablecoin reserve.

MARKET PULSE

Stocks Gave Up an Early Gain and Fell a Sixth Straight Day

Stocks lost their usual safety net on Thursday. Investors sold AI stocks, and a Fed still focused on inflation kept bonds from offering much shelter. The S&P 500 opened higher, then reversed and closed down 2.0% at 7,177 for its sixth straight loss. The Nasdaq fell 2.2%, and the Dow lost about 1,100 points.

The biggest names did not hold up. Nvidia (NVDA) fell 3.3% to a new 52-week low, and Amazon (AMZN), Anthropic's largest disclosed shareholder, lost 3.9%. The Cboe Volatility Index jumped more than 4 points to near 29. Neither bonds nor gold rose to offset the selling.

Investor Signal

A balanced portfolio loses its cushion when stocks fall and bonds hold still. That fits a market where rate and stock risks rise together. A day when Treasuries rally hard while stocks fall would weaken this reading and restore bonds as a hedge.

PREMIER FEATURE

Wall Street May Be Chasing Yesterday's AI Winners

While everyone watches the biggest AI names stumble, a new group of companies could be emerging as tomorrow's biggest winners.

Click here to learn more

RATES WATCH

Bonds Barely Rallied in the Selloff. Factories Raised Their Prices.

Bonds did little to soften the drop on a day when data showed prices rising even as demand cooled. The 10-year Treasury yield fell about 3 basis points, to 5.04%. Gold fell about 2% to a new 52-week low, below $3,670.

The Philadelphia Fed's factory survey showed both sides. Its activity index fell to 6.3 from 20.9, and new orders slipped below zero, a sign that demand is cooling. Yet factories' own price increases were the most widespread since June 2022.

Jobless claims edged up by 1,000 to 203,000, still a low level. Fed Vice Chair Jefferson said the AI buildout "is exerting upward pressure on demand and inflation." Kalshi traders put a quarter-point December hike at about 91% late Thursday.

Investor Signal

Weaker orders have not yet bought the Fed any relief on prices. That keeps a December hike priced in and limits how far yields can fall when stocks slide. Slower demand would normally argue for smaller hikes, but firm prices argue the other way. If other regional factory surveys show price pressure easing while orders stay weak, the case for a slower path gains ground.

AI WATCH

Anthropic Gave Back About Half Its Opening Gain. AMD Fell 8% on a Short Report.

Public buyers paid up for one AI company and marked down another. Anthropic (ANT) first traded at $111.50, about 34% above its $83 offering price. It slid for much of the session and closed at $97.17, still about 17% above the offering price.

AMD (AMD) fell 7.7% to about $489 after a short seller's report. Hunterbrook, which wrote it, has an affiliate that is short the stock. The report said a blacklisted Chinese server maker used newer AMD firmware. It also said its records do not, by themselves, show a broken export law. AMD said it complies with U.S. export-control laws and that the claims misrepresent its practices.

AMD's annual filing shows that about a third of 2025 revenue was billed to China, Hong Kong and Singapore. The filing notes that billing location is not always where chips end up.

Investor Signal

Investors are pricing policy risk into chip suppliers faster than into the AI firms that buy from them. Anthropic held well above its offering price in a falling market. AMD lost value on a claim that, by its author's own account, the records alone do not prove. With a third of its revenue billed to China, Hong Kong and Singapore, export rules sit at the center of AMD's value. If AMD shows licenses covering the companies named, the discount rests on an exposure investors already knew about.

FROM OUR PARTNERS

The REAL Reason Trump Is Invading Iran

For a moment…

Forget about Trump’s ties to Israel.

Forget about reports of Iran’s nuclear program.

Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.

Click here to find out what it is.

If you have even a single dollar invested in the U.S. stock market, this is going to directly impact you.

Discover the reason here.

RETAIL WATCH

Williams-Sonoma Met Forecasts and Fell 15%. Walmart Raised Its Outlook and Slipped.

Other retailers raised forecasts this week, but Williams-Sonoma (WSM) held its forecast steady. Its shares fell 15% even as comparable brand revenue rose 5.1%. Adjusted earnings of $2.19 a share roughly matched forecasts. Tariff refunds lifted reported margins, but the adjusted figure leaves them out.

Walmart (WMT) raised its full-year outlook for the third time this year. The new range was more conservative than analysts expected, and the shares fell 1%. Inventory grew 8.1%, faster than sales, though Walmart said that outside Flipkart, inventory grew more slowly than sales.

Investor Signal

Investors are paying for guidance that clears expectations, not for beats. When peers are raising, a steady forecast reads as a cut. Faster inventory growth at the largest retailer could point to holiday discounts. If Walmart's holiday margins hold despite that buildup, the caution in its shares looks overdone.

DEALS WATCH

Insmed Rose 21% on a Sanofi Report. Textron Sold a Unit to a Buyout Firm Below Book Value.

Buyers paid up for growth and paid less than book value for a slower business. Insmed added about $5 billion in value after Bloomberg reported that Sanofi is weighing a deal. Insmed (INSM) closed at $144.46, up 21%. No price has been reported, and Sanofi's shares fell.

Textron (TXT) agreed to sell its industrial unit to an affiliate of buyout firm Kingswood Capital for $1.2 billion in cash. The unit includes Kautex and golf-cart maker E-Z-GO. It expects a $350 million to $400 million charge, which means the price sits below the unit's book value. Textron plans to use the proceeds for buybacks in 2027. Its shares fell 2%.

Investor Signal

Buyers will pay a premium for fast growth and a discount for slow growth. Insmed's jump prices a bid that no company has confirmed. Textron took a loss to turn a slower business into cash for buybacks. If no Sanofi offer emerges, Wednesday's close becomes Insmed's reference point again. A reported price or a rival bidder would support the new level.

PARTNER SPOTLIGHT

FREE Gold Ticker to Buy ASAP: (NYSE:___)

Jim Rickards – the world’s #1 gold expert – has just revealed one of his favorite gold plays… 100% FREE

As Jim sees it, we’re witnessing the biggest gold boom of the last 100 years – and those who keep their money on the sidelines are missing their chance at a fortune thanks to gold’s epic run.

But smart investors who get in now, could make 10X their money in the coming months.

Click here to discover Jim’s FREE gold pick NOW.

CRYPTO WATCH

Nearly $2 Billion Left a Stablecoin Reserve. Coinbase Closed at a One-Year Low.

A legal risk turned into a cash drain for Sky, the stablecoin system once called MakerDAO. The USDC reserve behind its stablecoins fell about two-thirds. A report had tied about $518 million of swaps to wallets linked to hacks and sanctioned groups. Nothing was frozen or stolen. The reserve sits in one wallet that Circle (CRCL), which issues USDC, could freeze under a legal order. Holders left ahead of that risk.

Bitcoin offered no shelter either, slipping below $62,000 late Thursday. Coinbase (COIN) closed down 1.5% at a 52-week low, and Circle fell 2.7%.

Investor Signal

A stablecoin built to resist freezes is only as liquid as the dollars behind it, and those dollars can be frozen. Holders treated a legal risk as a cash risk and left before anyone acted. If Sky rebuilds the reserve without new outflows, the move reads as a precaution. Further withdrawals would point to a run on confidence.

CLOSING LENS

Thursday tested the usual hedges, and most of them failed. Stocks fell, bonds barely moved, and gold and bitcoin kept sliding. A Fed focused on inflation left little room for relief. Buyers still paid for Anthropic's debut and a possible Insmed bid. They marked down chip suppliers and retailers whose outlooks fell short. Until prices cool enough for bonds to rally again, their cushion will stay thin.

Big Pharma’s new ‘AI co-scientist’

…is already at work inside Bristol Myers Squibb.

Free report here →